NeuroSense Therapeutics Ltd. is set to participate in a key opinion leader (KOL) webinar titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)" on July 8, 2026, at 11:00 a.m. Eastern Time. Hosted by Roth Capital Partners, the event will address unmet needs in ALS treatment, clinical trial endpoint design, and the path forward for NeuroSense's lead candidate, PrimeC. The discussion will feature Professor Jeremy Shefner, Chair of Neurology at Barrow Neurological Institute, and Alon Ben-Noon, Chief Executive Officer of NeuroSense, moderated by Boobalan Pachaiyappan, Ph.D., Managing Director at Roth Capital Partners.

The webinar will examine PrimeC's positioning relative to the current standard of care and the objectives of the pivotal Phase 3 PARAGON study. NeuroSense has secured FDA clearance for this global trial, which aims to enroll approximately 300 participants, primarily in the United States. The company is advancing trial preparations and regulatory interactions across multiple jurisdictions, including Canada.

PrimeC Clinical Background

PrimeC is a novel extended-release oral formulation combining ciprofloxacin and celecoxib, designed to target neuroinflammation, oxidative stress, and dysregulated iron metabolism. The Phase 2b PARADIGM study previously demonstrated that PrimeC met its primary efficacy endpoint by achieving a statistically significant reduction in TDP-43 levels compared to placebo. TDP-43 is a pathological hallmark present in more than 97% of ALS cases.

Long-term follow-up data from the PARADIGM study indicated a statistically significant ~15-month median survival benefit. Additionally, NeuroSense reported positive biomarker findings from its Phase 2 RoAD proof-of-concept study in Alzheimer's disease, showing changes across biomarkers including TDP-43 and alpha-synuclein.

Alon Ben-Noon, Chief Executive Officer of NeuroSense, emphasized that the Phase 2b results provide compelling evidence supporting PrimeC's potential as a disease-modifying therapy. Prof. Merit Cudkowicz, Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, noted that the TDP-43 findings suggest target engagement of a central pathological process in ALS.

NeuroSense Therapeutics Ltd. has secured Japanese Patent 7857044 from the Japan Patent Office, covering its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The patent protection extends through 2042, strengthening the company's intellectual property portfolio following recent grants in the U.S., Australia, and Brazil. This development is significant for NeuroSense as it reinforces the proprietary position of its late-clinical stage treatment targeting severe neurodegenerative diseases.

The patent, titled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims. It safeguards the unique formulation and manufacturing process of PrimeC, specifically its synchronized delivery profile of celecoxib and ciprofloxacin. This mechanism is designed to target multiple key pathways underlying ALS progression, offering a novel approach to managing the disease.

Patent Details

The issuance of Japanese Patent 7857044 marks a milestone in NeuroSense's global intellectual property strategy. The patent's claims cover the specific combination and delivery method of the two active ingredients, which are central to PrimeC's therapeutic potential. By securing protection until 2042, NeuroSense aims to maintain a competitive edge in the ALS treatment landscape.

NeuroSense's PrimeC is currently in late-clinical stages, focusing on addressing the complex mechanisms of ALS. The recent patent approvals in multiple jurisdictions underscore the drug's innovative approach and the company's commitment to advancing treatments for neurodegenerative conditions.